A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A ‘C-reactive protein’ for psychiatrists and neurologists?
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Objective: Neurofilament light has shown promise as a biomarker for diagnosis, staging and prognosis in a wide range of neurological and neurodegenerative disorders. This study explored the utility of cerebrospinal fluid neurofilament light in distinguishing primary psychiatric disorders from neurodegenerative and neurological disorders, a common diagnostic dilemma for psychiatrists and neurologists. Methods: This cross-sectional retrospective pilot study assessed cerebrospinal fluid neurofilament light on patients referred to a tertiary neuropsychiatry service from 2009 to 2017 for diagnostic assessment of neuropsychiatric and neurocognitive symptoms, where a neurodegenerative disorder was a differential diagnosis, who received lumbar punctures as part of a comprehensive workup. The most recent gold-standard clinical consensus diagnosis was categorised into psychiatric disorder or neurodegenerative or neurological disorder. Data from healthy controls were available for comparison. Data extraction and diagnostic categorisation was blinded to neurofilament light results. Results: A total of 129 participants were included: 77 neurodegenerative or neurological disorder (mean age 57 years, including Alzheimer’s dementia, frontotemporal dementia), 31 psychiatric disorder (mean age 51 years, including schizophrenia, major depressive disorder) and 21 healthy controls (mean age 66 years). Neurofilament light was significantly higher in neurodegenerative or neurological disorder (M = 3560 pg/mL, 95% confidence intervals = [2918, 4601]) compared to psychiatric disorder (M = 949 pg/mL, 95% confidence intervals = [830, 1108]) and controls (M = 1036 pg/mL, 95% confidence intervals = [908, 1165]). Neurofilament light distinguished neurodegenerative or neurological disorder from psychiatric disorder with an area under the curve of 0.94 (95% confidence intervals = [0.89, 0.98]); a cut-off of 1332 pg/mL was associated with 87% sensitivity and 90% specificity. Conclusion: Cerebrospinal fluid neurofilament light shows promise as a diagnostic test to assist with the often challenging diagnostic dilemma of distinguishing psychiatric disorders from neurodegenerative and neurological disorders. Further studies are warranted to replicate and expand on these findings, including on plasma neurofilament light.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A few studies have highlighted the use of NfL as a biomarker for differential diagnosis between behavioural variant fronto temporal dementia and primary psychiatric disorders, with areas under the curve between 0•84 and 0•94.53,54”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [53]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 2×
“There has thus been a great deal of interest in its use as a biomarker in neurodegenerative and neurological conditions as a marker of neuronal damage (Khalil et al., 2018), and proposals to include it in biomarker guided diagnosis, in Alzheimer’s disease for example (Jack et al., 2018).”
BackgroundAssociation of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070
Ellis, K. A., Bush, A. I., Darby, D., De Fazio, D., Foster, J., Hudson, P., Lautenschlager, N. T., Lenzo, N., Martins, R. N., Maruff, P., et al. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009405 · Cited by 968 · cited 1×
“This study has been previously described by Ellis et al. (2009), but briefly, AIBL participants received a number of assessments, including clinical and neuropsychological assessment, amyloid PET imaging, CSF Aβ42, T-tau and P-tau.”
MethodSelf-citationDominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927 · cited 2×
“…and neurological diseases, with levels often elevated prior to the onset of clinical symptoms (Byrne et al., 2017; Gaiani et al., 2017; Mattsson et al., 2017; Preische et al., 2019; Rohrer et al., 2016; Scherling et al., 2014; Skillback et al., 2014; Weston et al., 2017; Zetterberg et al., 2015).”
BackgroundSelf-citationRoss, C. A., Margolis, R. L., Reading, S. A. J., Pletnikov, M., & Coyle, J. T. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.015 · Cited by 686
The diagnosis of young-onset dementia
Rossor, M. N., Fox, N. C., Mummery, C. J., Schott, J. M., & Warren, J. D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70159-9 · Cited by 586 · cited 2×
“…features and can be more likely to present with psychiatric features, compared to ‘typical’, lateonset or older-onset (age at onset greater than 65 years) presentations, contributing to higher rates of misdiagnosis and diagnostic delays of over 3 years (Draper et al., 2016; Rossor et al., 2010).”
BackgroundWoolley, J. D., Khan, B. K., Murthy, N. K., Miller, B. L., & Rankin, K. P. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06382oli · Cited by 549 · cited 3×
“…distinguishing Alzheimer’s disease from the ‘pseudodementia’ associated with major depression, and behavioural variant frontotemporal dementia (bvFTD) from schizophrenia, bipolar disorder or depression (Chan et al., 2014; Galimberti et al., 2015; Velakoulis et al., 2009; Woolley et al., 2011).”
BackgroundNeurocognitive impairment in drug-free patients with major depressive disorder
Porter, R. J., Gallagher, P., Thompson, J. M., & Young, A. H. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.3.214 · Cited by 519 · cited 2×
“…severe and complex issues are managed primarily by psychiatric services and do not get referred to (or have access to) tertiary neuropsychiatry services, and neurocognitive and neurological symptoms are common in psychiatric disorders (Bora et al., 2010; Porter et al., 2003; Thompson et al., 2005).”
Background
Cited by
Ducharme, S., Dols, A., Laforce, R., Devenney, E., Kumfor, F., van den Stock, J., Dallaire-Théroux, C., Seelaar, H., Gossink, F., Vijverberg, E., et al. (2020) · Brain · doi:10.1093/brain/awaa018 · Cited by 320
“CSF NfL appeared to be a good discriminator between neurodegenerative disorders and PPD (Eratne et al., 2020).”
BackgroundSelf-citationBoeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00341-0 · Cited by 218
The multifaceted role of neurofilament light chain protein in non-primary neurological diseases
Abu-Rumeileh, S., Abdelhak, A., Foschi, M., D'Anna, L., Russo, M., Steinacker, P., Kuhle, J., Tumani, H., Blennow, K., & Otto, M. (2023) · Brain · doi:10.1093/brain/awac328 · Cited by 118
Neurofilament-Light, a Promising Biomarker: Analytical, Metrological and Clinical Challenges
Coppens, S., Lehmann, S., Hopley, C. J., & Hirtz, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411624 · Cited by 114
Mousten, I. V., Sørensen, N. V., Christensen, R. H. B., & Benros, M. E. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.0645 · Cited by 108
Metadata
- Authors
- Eratne, D., Loi, S. M., Walia, N., Farrand, S., Li, Q.-X., Varghese, S., Walterfang, M., Evans, A., Mocellin, R., Dhiman, K., Gupta, V., Malpas, C. B., Collins, S., Masters, C. L., & Velakoulis, D.
- Affiliations
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- Delmont Private Hospital, Melbourne, VIC, Australia
- Edith Cowan University (AU)
- Corresponding author
- Eratne, Dhamidhu
- ORCID
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2019-06-21
- Volume
- 54
- Issue
- 1
- Pages
- 57-67
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2950813440
- Cited by
- 56
- References
- 36
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 11 · 2023: 9 · 2022: 8 · 2021: 11 · 2020: 6 · 2019: 1
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Australian & New Zealand Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Edith Cowan University Research Online (Edith Cowan University) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- the Trisno Family Research Grant in Old Age Psychiatry
- NorthWestern Mental Health Research Seed Grants
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
- Keywords
- neurofilament light chain, cerebrospinal fluid biomarkers, differential diagnosis, neurodegenerative diseases, mental illness, neurological disorders, Alzheimer's dementia, frontotemporal dementia, schizophrenia, major depressive disorder, diagnostic accuracy, neuropsychiatry, lumbar puncture, biomarker cut-off values, neuroinflammation, neurodegeneration biomarkers, neuropsychiatric symptoms
- MeSH terms
- Aged, Alzheimer Disease, Mental Disorders, Cross-Sectional Studies, Depressive Disorder, Major, Major Depressive Disorder, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Pilot Projects, Schizophrenia, Biomarkers, Neurofilament Proteins, Neurodegenerative Diseases, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A ‘C-reactive protein’ for psychiatrists and neurologists? https://app.cochat.ai/papers/10.1177/0004867419857811
- The paper
- Eratne, D., Loi, S. M., Walia, N., Farrand, S., Li, Q.-X., Varghese, S., Walterfang, M., Evans, A., Mocellin, R., Dhiman, K., Gupta, V., Malpas, C. B., Collins, S., Masters, C. L., & Velakoulis, D. (2020). A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A ‘C-reactive protein’ for psychiatrists and neurologists? Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/0004867419857811
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.